Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May;24(3):278-284.
doi: 10.1111/tbj.12952. Epub 2017 Nov 15.

Beyond sarcopenia: Characterization and integration of skeletal muscle quantity and radiodensity in a curable breast cancer population

Affiliations

Beyond sarcopenia: Characterization and integration of skeletal muscle quantity and radiodensity in a curable breast cancer population

Marc S Weinberg et al. Breast J. 2018 May.

Abstract

Skeletal muscle loss, commonly known as sarcopenia, is highly prevalent and prognostic of adverse outcomes in oncology. However, there is limited information on adults with early breast cancer and examination of other skeletal muscle indices, despite the potential prognostic importance. This study characterizes and examines age-related changes in body composition of adults with early breast cancer and describes the creation of a novel integrated muscle measure. Female patients diagnosed with stage I-III breast cancer with abdominal computerized tomography (CT) scans within 12 weeks from diagnosis were identified from local tumor registry (N = 241). Skeletal muscle index (muscle area per height [cm2 /m2 ]), skeletal muscle density, and subcutaneous and visceral adipose tissue areas, were determined from CT L3 lumbar segments. We calculated a novel integrated skeletal measure, skeletal muscle gauge, which combines skeletal muscle index and density (SMI × SMD). 241 patients were identified with available CT imaging. Median age 52 years and range of 23-87. Skeletal muscle index and density significantly decreased with age. Using literature based cut-points, older adults (≥65 years) had significantly higher proportions of sarcopenia (63 vs 28%) and myosteatosis (90 vs 11%) compared to younger adults (<50 years). Body mass index was positively correlated with skeletal muscle index and negatively correlated with muscle density. Skeletal muscle gauge correlated better with increasing age (ρ = 0.52) than with either skeletal muscle index (ρ = 0.20) or density (ρ = 0.46). Wide variations and age-related changes in body composition metrics were found using routinely obtained abdominal CT imaging. Skeletal muscle index and density provide independent, complementary information, and the product of the two metrics, skeletal muscle gauge, requires further research to explore its impact on outcomes in women with curable breast cancer.

Keywords: aging; breast cancer; geriatric oncology; sarcopenia; skeletal muscle index.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Scatter plots of SMI and SMD
(A) Skeletal Muscle Index (SMI) versus Age of Diagnosis. (B) Skeletal Muscle Density (SMD) versus Age of Diagnosis. (C) SMI versus Body Mass Index (BMI). (D) SMD versus BMI. (E) SMI versus Visceral Adipose Tissue (VAT). (F) SMD versus VAT. rho and slopes (m) for the correlations are indicated on the individual graphs. VAT values were drawn on a log2 scale based on the wide ranging data stratification, and the best fit line represents a straight line fit.
Figure 2
Figure 2. Scatter plot of SMI versus SMD
Skeletal Muscle Index (SMI) is plotted against Skeletal Muscle Density (SMD). R2 value and slope (m) for the correlation is indicated on the graph.
Figure 3
Figure 3. Scatter plot of SMG versus Age
Skeletal Muscle Gauge (SMG) is plotted against Age of Diagnosis. AU, arbitrary units (Skeletal Muscle Index [SMI] × Skeletal Muscle Density [SMD]). R2 value and slope (m) for the linear regression is indicated on the graph.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. - PubMed
    1. Wildiers H, Kunkler I, Biganzoli L, Fracheboud J, Vlastos G, Bernard-Marty C, et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol. 2007;8(12):1101–15. - PubMed
    1. Rier HN, Jager A, Sleijfer S, Maier AB, Levin MD. The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature. Oncologist. 2016 - PMC - PubMed
    1. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15(8):2920–6. - PubMed
    1. Villasenor A, Ballard-Barbash R, Baumgartner K, Baumgartner R, Bernstein L, McTiernan A, et al. Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study. J Cancer Surviv. 2012;6(4):398–406. - PMC - PubMed

Publication types